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INTRODUCTION AND LITERATURE REVIEW
History
Cystic Fibrosis (CF) is an inherited disease and affects mostly the respiratory and
digestive system, causing increased viscosity of the secretions in the lungs and the pancreas, thus
reducing life expectancy (Davis, 2006). Symptoms of CF have been documented as early as
3,000 BC (Busch, 1990); however, the entire spectrum of CF was not recognized and well
documented until the 1930s. In 1936, a Swiss pediatrician named the illness “celiac syndrome”,
and defined it as changes in the pancreas and bronchiectasis as observed in children (Fanconi,
Uehlinger & Knauer, 1936). The disease was characterized by malabsorption of fat and protein,
steatorrhea, growth failure, and pulmonary infection. Then in 1938 an American pathologist, Dr.
Dorothy Andersen, described the illness in the medical literature as “cystic fibrosis of the
pancreas”, after performing numerous autopsies on patients with this issue (Anderson, 1938). It
was due to her efforts that it was identified as a distinct clinical entity and identified as familial
in nature. Prior to this many cases of CF in general pediatrics were misdiagnosed as whooping
cough, chronic bronchitis, or pneumonia. When this was identified as a pathologic diagnosis,
life expectancy was approximately six months. It was theorized that CF was an autosomal
recessive disease believed to arise from abnormal mucus plugging of the exocrine ducts and
death often occurred from lung infection (Davis, 2006). Studies mainly focused on
abnormalities in mucus however, later in 1948 it was noted that many of the infants with CF
presented with heat prostration (excessive sodium and chloride concentration in sweat), which
offered a convenient diagnostic sweat test that is still used today (Davis, 2006). In the mid1950’s, patients with CF began to assemble into centers for care for physicians to become
familiar with clinical manifestations of the disease and gained experience with treatment.
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Matthews and colleagues (1964) established three pillars of treatment: nutritional repletion
(pancreatic enzyme supplements); relief of airway obstruction (postural drainage and clapping);
and antibiotic therapy of the lung infection (e.g., oral, intravenous). In the late 1980s, another
breakthrough occurred which was the identifying of the CF gene (Knowles et al, 1983; Boucher,
Stuffts, Knowles, Cantley, & Gatzy, 1986; Kerem et al, 1989). The diagnosis could then be
made by direct identification of two mutant CF alleles (CFTR, CF transmembrane conductance
regulator protein) in a cAMP-regulated chloride channel, which lead to more possibilities of gene
replacement therapies as part of the treatment for CF (Gibson, Burns & Ramsey, 2003).
Current
Substantial advances in basic and clinical research catalyzed therapeutic improvements
due to earlier diagnosis through screening. Better treatment and access to health care have
improved care and treatments of patients with CF. In America, approximately 30,000 people are
living with CF as of 2013, with half the population being 18 years or older (Cystic Fibrosis
Foundation Patient Registry, 2013). By obtaining a better understanding of the disease and
through improving treatment options, life expectancy has been increasing continuously over the
past 20 years. The prognosis for CF has improved dramatically from about six months to the
median survival age to now exceeding more than 35 years today (FitzSimmons, 1993; Davis,
2006; Cystic Fibrosis Foundation Patient Registry, 2013; MacKenzie et al, 2014). As of this
time there is still no known cure for CF, but aggressive management and treatment can ease
these symptoms and reduce complications. CF requires an intensive, time-consuming treatment
of various therapies, such as gene therapy, protein modulation, rehydration of airway surface
and/or mucolytics, anti-inflammatories, and anti-infective agents (Davies, Ebdon & Orchard,
2014), which provides an individual with CF to live a fuller life less encumbered by their
2
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condition.
One of the known therapies to assist with cystic fibrosis is the use of aminoglycoside
(AGs) antibiotics. Since their introduction in 1944, multiple AG preparations have become
available, including gentamycin and tobramycin, and are often used when serious Pseudomonas
aeruginosa infections are treated (Flume et al, 2009; Ruhl, Cable & Martell, 2014). As CF
patients are prone to developing infections of the pulmonary and sinonasal systems, AG
antibiotics have a role in the management of exacerbations, maintenance therapy after
acquisition of Pseudomonas aeruginosa and its eradication (Prayle & Smyth, 2010; Davies et al,
2014). AG antibiotics, mainly tobramycin, are used as regular treatments for some patients with
CF. This class of antibiotic has concentration-dependent effects on bacteria (i.e., increased
killing as concentrations are increased), suggesting there is greater efficacy at higher
concentrations (McKinnon & Davis, 2004), although the optimum concentration for treatment of
lung infections in CF has not been established. AGs may be administered intravenously or by
inhalation of a nebulized solution. Both approaches aim to maximize AG delivery to the
airways, the site of chronic infection, usually dosed according to body weight or surface area,
and serum levels guide subsequent doses in a course. Inhaled therapy delivers AGs directly to
the site of infection whereas intravenous doses achieve lower airway concentrations, but deliver
the medication to poorly ventilated lung regions (Prayle & Smyth, 2010). It is reported that the
use of AG ototoxicity may range between 60 to 85% of the population (Cystic Fibrosis
Foundation, 2013; Prescott, 2014). Typically patients with CF will be on a regimen of using
inhaled tobramycin daily for a cycle of 28 days then it will be discontinued for a cycle of another
28 days. When tobramycin is used in this fashion many patients with CF will be utilizing this
medication for many years. In addition to this many patients with CF will also receive the
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medication intravenously when admitted to the hospital.
Tobramycin is a bactericidal antibiotic that may adversely affect renal and
cochleovestibular systems however; no clear correlation exists between degree of nephrotoxicity
and ototoxicity (Henley & Schacht, 1988; Sone, Schachern & Paparella, 1998; Mulheran, Degg,
Burr, Morgan & Stableforth, 2001). Cochlear toxicity that results in hearing loss usually begins
in the high-frequencies and is secondary to irreversible destruction of outer hair cells in the organ
of Corti, predominantly at the basal turn of the cochlea. The exact mechanism of tobramycin
ototoxicity remains unknown however, many cellular processes have been implicated, and this
continues to be an active area of research (Gonzalez-Garrido, Vega, Mercado, Lopez & Soto,
2015).
There is a need to consider the benefit of the tobramycin treatment and its potential for
serious toxicity (Phillips & Bell, 2001; Al-Aloul et al, 2005; Glass, Plant & Spencer, 2005).
Patients with CF are particularly susceptible to side effects from exposure to usage of tobramycin
and their ototoxicity, but whether or not the potential risk of hearing loss is associated is
imperative. In the CF population, tobramycin has been shown to cause renal, nephrotoxicity and
ototoxicity (McCracken, 1986; Munckhof, Grayson & Turnidge, 1996; Forge & Schacht, 2000;
Nakashima, Teranishi, Hibi, & Kobayashi, 2000; Schacht, Talaska & Ryback, 2012; Huth et al,
2015), particularly when used for long and repeated courses (Sone et al, 1998; Phillips & Bell,
2001). It has also been shown that tobramycin ototoxicity is associated with the likelihood to
occur with larger doses, higher blood levels, or longer duration of therapy (Mulheran et al, 2001;
Prayle & Smyth, 2010; Ruhl et al, 2014). Specifically, a recent article estimated that
approximately 7% of all patients with cystic fibrosis exposed to tobramycin experience some
form of cochleotoxicity, although there is significant uncertainty associated with the risk, with a
4
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range of reported values from 0% to 16% (Mulheran et al, 2001).
More research have focused on prevalence of sensorineural hearing loss (SNHL) in CF
pediatric patients and its relationship to antibiotic use, however, research still varies in adults
with CF. Clinical assessment of these patients through pure-tone audiometry and brainstem
evoked response audiometry shows a prevalence of SNHL ranging from 0% to 17% of the CF
pediatric population (Haddad, Gonzalez, Kurland, Orenstein & Casselbrant, 1994; Ozcelik et al,
1996; Jorrisen, Boeck & Feenstra, 1998; Mulheran & Degg, 1997; Mulheran et al, 2001; Cheng
et al, 2009; Piltcher, Teixeira, Oliveira, Scattolin & Piltcher, 2003) and the adult population
(Kimberley, Brown & Eggermont, 1993; Mulheran et al, 2001; Suryanarayanan, Taylor & Tan,
2005). In opposition, studies have found no significant hearing loss in patients with CF, even
after an average of four repeated courses of tobramycin (Pedersen, Jensen, Osterhammel &
Osterhammel, 1987; Mulheran et al, 2001; Scheenstra, Heijerman, Zuur, Touw, & Rijntjes,
2010) or after single courses (Mulheran et al, 2006; Martins, Camargos, Becker, Becker &
Guimarães, 2010). It is typically seen and recommended across various publications of the use
of once-daily dosing to achieve optimal levels for efficacy while reducing the risk of toxicity
(Soulsby, Bell, Greville & Doecke, 2009; Smyth, 2010).
Due to the ototoxic effects of tobramycin it is recommended that ototoxic monitoring be
performed on patients with CF. Although assessing hearing acuity in the frequency range from
.25 to 8 kHz has become routine clinical practice, evaluating hearing sensitivity beyond 8 kHz is
necessary when monitoring hearing patients with CF that are receiving ototoxic medication(s).
High-frequency pure-tone audiometry is the most common method for assessing ototoxicity as it
begins to cause hearing loss at higher frequencies (i.e., 10, 12, 14, 16, 18, and 20 kHz). It is
known that these ultra high-frequencies are affected earlier than conventional frequencies due to
5
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exposure to ototoxicity (Fausti et al, 1999; Fausti et al, 1992). Therefore, high-frequency puretone audiometry is a useful tool to detect hearing damage at the earliest possible time. The early
detection of hearing damage not only warns clinicians to the status of the auditory insult but also
provides an opportunity for them to balance the therapeutic effects of drugs with the risks of
permanent hearing loss. It is recommended that patients receiving ototoxic medication have
hearing evaluations weekly to monitor the potential ototoxic effects of medication (ASHA, 1994;
AAA, 2009). However, as patients with CF receive treatments daily, every other month for
years it may not be feasible to monitor hearing weekly to determine hearing threshold shift.
Currently there is no other standard to potentially monitor hearing. The question then arises as to
whether or not there is a less time consuming option for the assessment of hearing on individuals
that may be relatively accurate in predicting and/or detecting early hearing loss.
Self-assessment tools have been developed to quantify patient’s subjective perceptions of
their hearing handicap regarding communication difficulties and their subsequent social and
emotional consequences. Some of the most common subjective questionnaires used today
include the original and screening versions of the Hearing Handicap Inventory for Adults
(HHIA) (Newman, Weinstein, Jacobson & Hug, 1990), and the Hearing Handicap Inventory for
the Elderly (HHIE) (Newman & Weinstein, 1988), which both provide individual’s subjective
impressions of their hearing status. The HHIE (used for adults over 64 years of age) and the
HHIA (later modified to be used for adults less than 65 years of age) have demonstrated to be
useful tools to quantify consequences of hearing loss for those with a hearing impairment
(Newman & Weinstein, 1988; Newman, Weinstein, Jacobson & Hug, 1991). The HHIA original
(25 items) and screening (10 items) versions have high internal consistency of its questions, testretest reliability and low standard error (Newman et al, 1991; Newman et al, 1990; Aiello, de
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Lima & Ferrari, 2011; Wolters, Johnson & Isaac, 2011). Such items cover various situations
where a hearing problem might cause difficulties or embarrassment, as shown in Appendix A,
with three possible answers to each item (i.e., ‘yes’, ‘sometimes’ and ‘no’). This tool can be
worthwhile additions to the audiologists and other professionals’ (e.g., physicians, primary care)
test battery as information obtained from the responses can help substantiate patient’s hearing
complaints not readily apparent. By results of conventional audiometric testing for example, this
may facilitate decisions regarding candidacy for amplification, assist in a counseling process,
serve as a guide designing a client-centered rehabilitation program and serve as a criterion
measure in documenting the effects of rehabilitation efforts, including hearing aid benefit. It can
also be used to better identify those that may be in need of a full audiometric evaluation,
especially where a hearing test cannot be administered in person in other health clinics.
There’s limited research in using subjective tools by other medical professionals other
than audiologists for other health conditions that can be at risk of hearing loss, such as adults
with cystic fibrosis. Other common medical areas regarding ear related issues include tumors,
traumatic injuries, autoimmune inner ear disease etc., however whether subjective tools express
patients’ concerns of any hearing disabilities is rare as these medical areas are addressing more
severe concerns of first priority. Such tools can be used in studies and other medical clinics
where a hearing test cannot be administered in person to detect patients who might display
possible hearing difficulties.
The present study aimed to verify the prevalence of SNHL in patients with CF using the
HHIA and HHIA-S questionnaires, and a comprehensive audiological evaluation to assess its
association with the use of AGs. Specifically, three questions were examined:
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1. If there is a difference between the original version (HHIA) and screening version
(HHIA-S) self-report questionnaires when administered to patients with CF.
2. Whether the HHIA and/or HHIA-S could be used to detect any hearing perception
difficulties in adult patients with CF.
3. If any factors related to aminoglycoside usage affects how patients with CF subjectively
perceive having any hearing loss or objectively show affected audiological results.
METHODOLOGY
Participants
47 participants were recruited from Washington University in St. Louis School of
Medicine’s (WUSM) Center for Advanced Medicine at the Adult Cystic Fibrosis Clinic in the
Division of Pulmonary and Critical Care Medicine via either a telephone script or flyer approved
by the Human Research Protection Office (HRPO). Using a priori power analysis and sample
size calculation utilizing G-Power 3.1.9.2 (http://mac. softpedia.com/get/Math-Scientific/GPower.shtml) calculated that 94 participants were needed to investigate differences in subjective
responses to hearing perception and results from the audiological evaluation testing (comparing
normal to mild hearing loss). The calculation was completed using a two-tailed test, alpha level
of 0.05, and power of 0.80. Due to limited time constraint of this study and lack of awareness in
patients with CF and varying hearing loss, the number of participants needed couldn’t be
achieved to have high statistical power.
Each participant signed an informed consent form approved by HRPO’s Institutional
Review Board (IRB) at the initial visit. For every participant, each testing session took
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approximately one hour or less. No compensation was provided and testing was only performed
on a voluntary basis.
The database used for the current study was de-identified, as to eliminate the possibility
of participant identification from data included within the database. In order to qualify for
entrance of the study, each participant was required to (a) be between the ages of 18 and 55
years; (b) be medically diagnosed with CF; (c) have not had any surgical procedures to their ears;
(d) be cleared via ear otoscopic examination bilaterally as to not have any potential causes of
sound blockage. Two participants were dropped from the study; one because he/she did not fit
the inclusion criteria (i.e., history of ear surgery), and the other did not complete the second half
of the study (i.e., audiological examination). Therefore, 45 participants were included for data

analysis.
This study required one visitation at the Vision and Hearing Center located at the Center
for Advanced Medicine where the Primary Investigator (PI) and the PI’s advisor evaluated
participants. Participants were seated in a double-walled sound-treated booth. The audiology
equipment is calibrated annually following American National Standards Institute (ANSI,
2004b) and quarterly by the audiology faculty. A case history was taken to collect demographic
information. Example responses included any usage of tobramycin AG antibiotics via
intravenous (IV) therapy and/or inhaler, duration of use of the medication and other factors
related to ear problems (i.e., tinnitus, pressure, otalgia, dizziness, family history of hearing loss,
and noise exposure). Otoscopy was completed to ensure the ear canals were clear bilaterally.
HHIA & HHIA-S
The HHIA is a 25-item, self-assessment scale composed of 13-item emotional and 12item social/situational subscales (Appendix A) that was administered to each participant. The
9
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HHIA-S contains 10 items, five emotional and five social/situational, selected from the 25-item
version of the HHIA. The items comprising the HHIA-S are denoted with an asterisk (*), as
seen in Appendix A. Example items exhibiting as emotional scenarios include, Does a hearing
problem cause you to feel embarrassed when meeting new people? and Do you feel handicapped
by a hearing problem? Example items exhibiting as social/situational scenarios include, Does a
hearing problem cause you difficulty in the movies or theater? and Does a hearing problem
cause you difficulty when in a restaurant with relatives or friends? For both scales, a “yes”
response to an item was given four points, “sometimes” of two points, and “no” response of zero
points. Scores for the total HHIA range from 0 to 100, with categorical ranges of 0 to 20 having
no handicap, 22 to 60 having mild to moderate handicap, and 62 to 100 having severe handicap.
Scores for the total HHIA-S range from 0 to 40, with categorical ranges of 0 to 8 having no
handicap, 10 to 24 having mild to moderate handicap, and 26 to 40 having severe handicap.
Higher score values indicate greater perceived handicap in hearing. HHIA-S scores were
determined by extracting responses of the appropriate 10 items from the longer version. Both
questionnaires evaluated the total scores, and subtotal scores representing only emotional items
and only social/situational items. If the total scores fall in the handicap range (i.e., Mild to
Moderate Handicap, or Severe Handicap) of severities of subjectively perceiving hearing loss,
this could be a possible indication that the patient should be referred for an audiological
evaluation, however no studies used specific cut-offs for patient medical referral.
All participants received in-person administration of the HHIA before the audiologic
evaluation, allowing privacy to complete each item. Each participant responded to each item,
and once finished, the HHIA was collected and not scored until after the entire test session.
Audiologic Evaluation
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Prior to testing, each participant underwent otoscopic examination with a standard
otoscope utilized to view each ear canal and tympanic membrane (eardrum). Any abnormalities
that could potentially affect test results or prevent sound passing through the ear(s), such as
cerumen and/or debris impaction, absent or abnormal visual of the eardrum, or other obstructions
were not further tested and excluded from the study.
A comprehensive audiologic evaluation was performed on each participant in a soundtreated booth using the protocols from the Adult Division of Audiology clinic using the Grason
Stadler GSI-61 audiometer (ANSI, 2004a). Conventional pure-tone air-conduction (pulsed
tones) was measured per ear using TDH-50P Telephonic supra-aural headphones at octave and
mid-octave interval frequencies (i.e., .25, .5, 1, 2, 3, 4, 5, and 8 kHz) to determine the
participant’s thresholds (softest hearing level). Pure-tone bone-conduction (pulsed tones) was
measured per ear using a bone oscillator at each standard and octave frequency (i.e., .25, .5, 1, 2,
3, and 4 kHz) to determine the participant’s thresholds. If there was a significant difference
between right and left ear thresholds (≥40 dB HL) at the same frequency, a masking procedure
took place to separate the two ears, acoustically, using narrow band noise (NBN) to determine
accurate thresholds. Thresholds for pure-tone air-conduction and bone-conduction of 15 dB HL
or less indicated normal hearing, 16 to 25 dB HL indicated sight hearing loss, 26 to 40 dB HL
indicated mild hearing loss, 41 to 55 dB HL indicated moderate hearing loss, 56 to 70 dB HL
indicated moderately-severe hearing loss, 71 to 90 dB HL indicated severe hearing loss, and 91
dB HL and above indicated profound hearing loss. To determine type of hearing loss, an airbone gap (ABG) difference of more than 10 dB HL indicated a conductive hearing loss, an ABG
difference of less than or equal to 10 dB HL indicated a sensorineural hearing loss, and a
combination of conductive and sensorineural indicated a mixed hearing loss.
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Speech recognition thresholds (SRTs) were determined at the softest level of intensity
(dB HL) using monitored live voice (MLV) (with voice peaking at 0 dB on the VU meter) at
which familiar two-syllable spondee words (e.g., “baseball”, “toothbrush”, “railroad”) may be
heard and repeated by the participant per ear. SRTs that are within ±6 dB HL of pure-tone
average (PTA) air-conduction thresholds are considered to be in an agreement of each other,
with an addition indicator that speech thresholds of 15 dB HL or less to be considered normal
speech understanding. Word recognition (WRS) percentage scores were determined by the
correct number of one-syllable words from the NU-6 word lists (e.g., “boat”, “home”, “knock”)
using a recording of a female speaker. This was presented at comfortable listening levels of 40+
dB Sensation Level (SL) (louder) in reference to their SRT score per ear. Participants repeated
25 word-lists if two or less words were incorrectly produced, otherwise repeated the full 50
word-list. WRS scores ranging from 90% to 100% indicated normal word recognition, 76% to
88% indicated slight difficulty, 60% to 74% indicated moderate difficulty, 50% to 58% indicated
poor recognition, and scores less than 50% indicated very poor recognition.
Ultra high-frequency evaluation was administered per ear using the high-frequency
Madsen Itera II audiometer inside the booth with Senheiser HAD 200 supra-aural headphones.
This was tested using high-frequency octaves (i.e., 9, 10, 11.2, 12.5, 14, and 16 kHz) to find the
participant’s softest hearing level. Thresholds ≤15 dB HL for each high-frequency measurement
was considered normal hearing.
Immittance audiometry was administered outside of the audiometric test booth using the
GSI Tympstar (immittance machine). Tympanometry procedure recorded compliance and
middle ear pressure per ear for each participant using a 226 Hz tone via probe. Normal
tympanometry measurements and results per ear include a canal volume to be from 0.6 to 2.0 ml,
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peak pressure to range ±100 daPA, and static admittance to be from 0.3 to 1.5 mmhos.
Acoustic reflex thresholds were recorded for middle ear reflex muscle retractions at highintensity stimuli per ear, measuring ipsilateral and contralateral responses at different frequencies
(i.e., .5, 1, 2, and 4 kHz). Normal (present) results indicated acoustic reflex thresholds to range
between 70 to 100 dB HL with repeatable compliance change of 0.02 ml or greater. If acoustic
reflex thresholds are present and at adequate intensity levels (i.e., ≤100 dB HL), acoustic reflex
decay was performed to measure the decline of muscle contraction at 10+ dB SL in reference to
their previous acoustic reflex threshold (tested only at .5 and 1 kHz, if applicable). Normal
acoustic reflex decay needed to remain steady for 10 seconds, revealing present amplitude.
Statistical Analysis
Correlational studies were completed to allow for analysis of relationships between each
of the variables of interest. Using the software program R (R Core Team, 2015; Revelle, 2015),
bivariate correlational analyses were completed for demographic characteristics, self-report
questionnaire items, and audiometric evaluation results. Pearson correlational coefficients were
calculated for each set of variables and significance was determined at the p <0.05 levels, as
specified by asterisks in the Tables used for this study. Tables were compiled using the stargazer
package (Hlavac, 2015) and graphs were compiled using tidry (Wickham, 2016) and ggplot2
packages (Wickham & Chang, 2015).
RESULTS
General Characteristics
Participants
Data from all 45 qualified participants was analyzed to determine the validity of the
HHIA and HHIA-S in correlation to their audiometric evaluation and demographic variables.
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The CF participants ranged from 18 to 51 years, with the average age at 31.2 (SD = 8.2) years.
Forty percent were female, with a mean age of 30.4 (SD = 8.87) years and sixty percent were
male, with a mean age of 31.7 (SD = 8.04) years. There is no significant difference (p > .05)
between men (N = 27) and women (N = 18) in pure-tone audiometry results, as well as no
significant difference (p > .05) between right and left ears across conventional and highfrequency pure-tone testing. Those who have reported tinnitus (N = 21) compared to those who
did not report having tinnitus (N = 24) were compared and they are not significant (p > .05).
HHIA and HHIA-S
The HHIA and HHIA-S were examined to find a relationship between the two self-report
scales and were very highly correlated (r > .85), giving identical results. The relationship of total
scores and subscales (i.e., Emotional vs. Social/Situational) from the questionnaires were
examined and the average correlation was 0.92 and the smallest correlation was 0.82.
Therefore, the two scales are nearly identical and will focus on using the longer questionnaire
(i.e., HHIA) for better estimates of self-report perception of hearing loss for the remaining of this
study.
Audiological Evaluation
In Figure 1, hearing thresholds (dB HL) for all participants are represented on an
audiogram-like representation across conventional frequencies (i.e., .25 to 8 kHz) for right and
left ear. Average hearing thresholds, the red line as demonstrated from Figure 1, are displayed
for each ear. Average hearing thresholds for the right ear are as followed: 15 dB HL at .25 kHz;
13 dB HL at .5 kHz; 9 dB HL at 1 kHz; 9 dB HL at 2 kHz; 11 dB HL at 3 kHz; 10 dB HL at 4
kHz; 12 dB HL at 6 kHz; 14 dB HL at 8 kHz. Average hearing threshold for the left ear are as
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followed: 11 dB HL at .25 kHz; 10 dB HL at .5 kHz; 8 dB HL at 1 kHz; 6 dB HL at 2 kHz; 12
dB HL at 3 kHz; 13 dB HL at 4 kHz; 16 dB HL at 6 kHz; 19 dB HL at 8 kHz.
In Figure 2, hearing thresholds for all participants are represented on an audiogram-like
representation across ultra high-frequencies (i.e., 9 to 16 kHz) for right and left ear. Average
hearing thresholds, the red line as demonstrated from Figure 2, are displayed for each ear.
Average hearing thresholds for the right ear are as followed: 19 dB HL at 9 kHz; 19 dB HL at 10
kHz; 21 dB HL at 11.2 kHz; 18 dB HL at 12.5 kHz; 23 dB HL at 14 kHz; 23 dB HL at 6 kHz.
Average hearing threshold for the left ear are as followed: 22 dB HL at 9 kHz; 22 dB HL at 10
kHz; 25 dB HL at 11.2 kHz; 26 dB HL at 12.5 kHz; 25 dB HL at 14 kHz; 20 dB HL at 16 kHz.
The comparison of all participants was examined against baseline levels of normal
hearing threshold (≤15 dB HL) and is shown in Table 1. This sample showed significantly
poorer hearing on several of the high-frequency variables in the left ear (i.e., 9, 10, 11.2, 12.5,
and 14 kHz) and right ear (i.e., 11, 14, and 16 kHz).
HHIA Scores and Audiological Evaluation
Correlations were examined between the HHIA total and subtotal scores (i.e., Emotional
and Social/Situational) and results of the air-conduction and bone-conduction conventional
audiometry. Values that are statistically significant (p < .05, greater than r = .4) are shown in
Table 2. Air-conduction frequencies are significant (p < .05, greater than r = .4) for total and
subtotal HHIA scores for both ears at .25 and .5 kHz and for pure-tone average. In the right ear,
there’s significance (r = .4) across all HHIA scores at 1, 4, 6, and 8 kHz, and in the left ear,
there’s significance across all HHIA scores at 2 kHz. Only bone-conduction at .25, .5 and 4 kHz
right ear only show significance across all HHIA scores. The rest of the conventional
audiometry results show substantially large non-significant correlations with the HHIA. Figures
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3 and 4 show graphical correlations between the relationships of the HHIA scores and
conventional audiometry results (i.e., pure-tone air-conduction and bone-conduction), showing a
stronger correlation.
Correlations were examined between the HHIA total and subtotal scores (i.e., Emotional
and Social/Situational) and results of ultra high-frequency audiometry as shown in Table 3. As
all correlations were approximately .2 or .3, it is not statistically significant (greater than r = .4)
across all frequencies. Figure 5 shows small correlations, again, not statistically significant.
There were no significant correlations between the HHIA questionnaire and speech
audiometry (i.e., SRT and WRS), as well as immittance audiometry (i.e., tympanometry, ART
and reflex decay), therefore will not be discussed regarding statistical analyses for the remainder
of the study.
Of the 45 participants, a comparison was made between the self-report response scores
(i.e., Normal Handicap, Mild to Moderate Handicap, and Severe Handicap) to the objective
audiological results of the hearing test (i.e., normal hearing vs. abnormal hearing). For example
in Table 4, you’ll see pure-tone averages of the right (Table 4A) and left (Table 4B) ears were
compared to self-report responses. Very few participants (i.e., Table 4A Right Ear: N = 3 report
Mild to Moderate Handicap; N = 1 report Severe Handicap; Table 4B Left Ear: N = 1 report
Mild to Moderate Handicap; N = 1 report Severe Handicap) experience abnormal hearing, as
measured both objectively and subjectively. This sample size is too small to compare
differences between objectively hearing impaired participants and normal hearing participants.
However, there seems to be a number of participants with normal hearing (Table 4A Right Ear:
N = 35; Table 4B Left Ear: N = 37) who report perceiving of having a mild hearing impairment
(i.e., Mild Handicap response range).
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Of all participants, only 39 reported Mild to Moderate Handicap or Severe Handicap on
the HHIA (defined as 22+ points). Only 1 participant reported Severe Handicap (defined as 62+
points) so they cannot be assessed separately. Therefore, those reported Mild to Moderate
Handicap or Severe Handicap is compared to the baseline of Normal hearing (≤15 dB HL), as
shown in Table 5. Despite reporting hearing loss, participants only demonstrated significance (p
< 0.5) objectively at two of the ultra high-frequencies (i.e., left ear at 11 and 12 kHz) and no
significance (p > 0.5) at conventional frequencies.
Aminoglycoside - Tobramycin, HHIA Scores, and Audiological Evaluation
The relationship between the age of CF diagnosis and the age onset of receiving
tobramycin treatment is compared to self-report questionnaire responses, and conventional and
ultra high-frequency pure-tone audiometry tests, as shown in Table 6. There are significant
correlations (greater than r = .4; p < .05) between the age of CF diagnosis and the age receiving
tobramycin treatment with results of ultra high-frequency audiometry testing. Participants who
were diagnosed at a later age showed affected ultra high-frequency audiometry (r = .52, p < .05).
Increase in age at diagnosis is also correlated with increase in age of tobramycin treatment
received (r = .56, p < .05); however there is some variability in how much later after CF
diagnosis that treatment of tobramycin began.
At the time of the study, all participants were asked if he or her were currently taking any
tobramycin medication or not, whether it was via inhale or IV therapy. As there was only one
affected frequency (i.e., air-conduction at 2 kHz in right ear) correlated between the status of
intake at time of test with the self-report responses and audiometric pure-tone testing, this data
was not enough to show any significance in this relationship.
Type of Tobramycin Intake
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Between type of intake of tobramycin, 16 participants have only used inhaled, 1
participant only used IV therapy and 26 participants have used both. Because only one
participant used IV therapy only, this cannot be comparable to inhaled participants only or those
that use both. Shown in Table 7, participants who inhale tobramycin (N = 0) were compared to
participants who do not (N = 45), and shown in Table 8, those who use IV therapy (N = 27) to all
participants who do not (N = 18). None of the tests are significant (p > .05) in regards to the
comparisons of participants inhaling to those not, and participants who use IV therapy to those
do not.
An independent sample t-test was used to compare ages of participants using inhalation
to those not using inhalation. There is no difference in age between patients who inhaled (M =
31.19, SD = 8.44) and those who did not (M = 30.67, SD = 7.51; t(43) = -0.1, p = 0.92). An
independent sample t-test was used to compare ages of patients using IV therapy to those not
using an IV. There is no difference in age between participants who use IV therapy (M = 31.11,
SD = 7.81) and those who did not (M = 31.22, SD = 9.23; t(43) = 0.04, p = 0.97). An
independent sample t-test was used to compare the ages of participants using tobramycin at the
time of testing and those not using tobramycin. There is no difference in age between
participants who were using tobramycin at the time of testing (M = 31.17, SD = 77.63) and those
who did not (M = 31.14, SD = 9.14; t(43) = -0.01, p = 0.99).
Duration of Tobramycin
Two groups were separated in the duration of using tobramycin, Group 1 consisting of 25
participants (56%) using tobramycin 10 years or less, and Group 2 consisting of 20 participants
(44%) using tobramycin more than 10 years. Table 9 shows the means and SD of each group on
each of the conventional air-conduction pure-tone frequencies and the statistical test of the
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difference (p = .05). Only one of the tests is significant (p < .05), which was 250 Hz in the right
ear. However, in general, there is no correlation between duration of tobramycin and
conventional audiometry testing. Yet, it is observed that participants with CF who had been
taking tobramycin for 10 years or fewer scored lower (M = 4.2, SD = 6.56) on the self-report
questionnaire than participants with CF who had been taking tobramycin for more than 10 years
(M = 14.5, SD = 23.78; t(43) = -2.07, p < . 05).
The comparison of participants using tobramycin for 10 years or fewer were examined
against baseline levels of normal hearing threshold (≤ 15 dB HL) and is shown in Table 10.
This sample showed significantly worse hearing on a few high-frequency variables in the right
ear (i.e., 14 and 16 kHz) and left ear (i.e., 14 Hz). In Table 11, it’s showing the comparison of
participants using tobramycin for more than 10 years compared to baseline normal hearing
threshold (≤ 15 dB HL). This sample showed significant worse hearing on several of the highfrequency variables in the right ear (i.e., 9 and 11 kHz) and in the left ear (i.e., 8, 9, 10, 11, and
12 kHz). Figure 6 graphically represents the average hearing thresholds (dB HL) across
conventional and ultra high-frequencies, differentiating the duration of tobramycin medication
intake in participants with CF (10 years or fewer compared to more than 10 years). Again, there
is no correlation however those using tobramycin more than 10 years shows poorer hearing
thresholds on the graph than those using tobramycin for 10 years or fewer.
DISCUSSION
Recent studies have shown patients with CF to be at high risk for SNHL (Cheng et al,
2009; Mulheran et al, 2001; Tarshish et al, 2016), however others have not (Mulheran et al,
2006; Scheenstra et al, 2010). In this study of patients with CF, there is no validity in hearing
perception from the subjective questionnaire responses with the audiometric testing to detect
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hearing loss. Even though the original (HHIA) and screening (HHIA-S) questionnaires can
either be administered as they reveal similar outcomes and high correlations, this self-report may
not be an efficient tool to detect hearing perception difficulties in adults with CF.
HHIA Scores and Audiological Evaluation
Positive values at frequencies listed in Table 2 indicate that as a patient self-reports
greater hearing loss (i.e., Mild to Moderate, and Severe Handicap), the results of the objective
hearing test indicated greater hearing loss. However, many non-significant correlations are still
substantially large. With the limited number of participants, there is not enough correlation in
the relationship between the self-reports of hearing loss and the objective tests across frequencies
and there are discrepancies in the interpretation. For example, of the participants who self-report
normal hearing (HHIA score ranging from 0 – 20), most do have normal hearing. However, of
the participants who report Mild to Moderate Hearing Handicap (HHIA score ranging from 22 –
60), objectively normal hearing in conventional audiometry is found. Clinically, this can lead to
difficulty with decision-making regarding referrals from a medical professional, due to lack of
consistency. Overall, this suggests that even though there is a strong relationship between selfreported hearing loss and objective measures of hearing loss, not all patients show consistency.
Therefore, some patients who are suffering from hearing loss are subjectively experiencing
hearing loss; however some patients report hearing loss when they actually have normal hearing.
Even though there weren’t enough participants with CF showing various objective
hearing loss results, it was anticipated that ultra high-frequency thresholds would be affected
more, as there is potential side effects of tobramycin and its ototoxicity at pitches above 8000 Hz
(Fausti et al, 1999; Fausti et al, 1992). There was no statistical significance between the HHIA
scores and ultra high-frequency audiometric results, therefore this shows that the HHIA self-
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report questionnaire would not be a good tool to detect a patient’s hearing loss in this population
at those measured frequencies (i.e., >8 kHz). However it should be noted that common speech
sounds, used in daily communication, are produced more at conventional frequencies (i.e.,
between .25 and 8 kHz), which is why those frequencies are commonly tested for a conventional
audiological evaluation (Jongman, Wayland & Wong, 2000; Pittman, Stelmachowicz, Lewis, &
Hoover, 2003). Decrease in hearing thresholds at conventional frequencies may cause patients to
realize difficulty with missing speech or have trouble hearing in a variety of listening
environments. Even if patients demonstrated hearing loss at higher frequencies but normal
hearing at conventional frequencies, hearing difficulty might not be noticeable to the patient
regardless. Therefore, the HHIA would not be useful in medical clinics that assist patients with
risks of ototoxicity, as it may not detect changes in hearing at ultra high-frequencies. It may be
useful in detecting hearing loss at more conventional speech frequencies, however if ototoxicity
is the cause of the hearing loss, irreparable damage may already have occurred to the ultra highfrequency region of the cochlea resulting in permanent hearing loss and tinnitus.
As seen in Table 5, again, there is no correlation with self-reported hearing loss and puretone testing when comparing Mild to Moderate Handicap and Severe Handicap to Normal
hearing on the self-report questionnaire. Using the cutoffs (i.e., ≤15 dB HL for conventional and
ultra high-frequencies), the HHIA does not adequately assess hearing loss. Different
audiological clinics may use various cutoffs of what is considered normal hearing in the adult
population or during ototoxic monitoring, ranging from 15 – 25 dB HL whether in conventional
and/or higher frequency testing. It should also be noted that during ototoxic monitoring, there is
more importance in monitoring ultra high-frequency thresholds to stay within ±10 dB HL
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(Konrad-Martin et al, 2005), which is why there may be a lack in standard norms of cutoffs in
those higher regions of audiometry testing.
As there was a lack of CF participants that demonstrated abnormal hearing, sufficient
data was not available to demonstrate any correlations with speech audiometry testing (i.e., SRT
and WRS) or immittance testing (i.e., tympanometry, ART). These two tests are typically
performed at baseline testing, however subsequent testing may not be performed for ototoxic
monitoring unless a significant change occurs in hearing threshold (AAA, 2009; Campbell &
Durrant, 1993; Campbell, 2004). Even though some patients might report little to no hearing
difficulties, it does not appear that any of these individuals meet threshold for objective hearing
loss, therefore speech audiometry and immittance tests do not capture true hearing loss in the CF
population.
Aminoglycoside - Tobramycin, HHIA Scores, and Audiological Evaluation
From Table 6, correlations with the age that participants with CF have been diagnosed
and when they received treatment, in relationship with pure-tone testing are demonstrated. As
patients with CF were diagnosed later in age as well as when they received treatment, it seems as
though regions at higher frequencies (>8 kHz) are more affected (poorer hearing) than
conventional frequencies (≤ 8 kHz) (better hearing). This supports various research studies as to
the importance in monitoring ultra high-frequency thresholds in populations who undergo
treatment with tobramycin (Mulheran et al, 2001; Schacht et al, 2012; Huth et al, 2015; Fausti et
al, 1999; Fausti et al, 1992). There should be some consideration in frequent ototoxic monitoring
if a patient with CF is later diagnosed and treated than earlier, but whether or not there’s an age
cut-off of onset of diagnosis or treatment is needed to be further investigated.

22

Spejcher
No difference was noted whether or not participants with CF were currently being
medicated with tobramycin or not at the time of testing. Therefore, this area may be more useful
in a longitudinal study that examines repeatable audiological testing (e.g., monthly following 28
day cycles) and whether or not actively using tobramycin is correlated with hearing thresholds in
pure-tone testing.
Type of Tobramycin Intake
There are no significant correlations with the type of tobramycin usage (i.e., inhale, IV
therapy) or age of the CF participants in comparison to their audiological evaluation. This is
most likely due to the small sample size and limited number of participants that demonstrated
hearing loss. In relation, other literature has found no differences in type of tobramycin therapy
that was associated with detectable renal toxicity or ototoxicity in this population (Wagener et al,
2013; Hennig et al, 2014). Therefore, further research should investigate this area in a larger
sample population and include groups who objectively have hearing impairment.
Duration of Tobramycin
Inhalation of tobramycin for 10 years and fewer or greater than 10 years, did not affect
the audiological tests at conventional frequencies. Even though there is statistical significance at
one frequency, it is not enough data to support a relationship. However, it is interesting to note
that patients with CF who had been taking tobramycin for greater than 10 years have higher
threshold averages in conventional air-conduction pure-tones (poorer hearing) than patients who
had been taking tobramycin for 10 years or less (as shown in Figure 6). This relationship
demonstrates that there might be some association in whether or not patients with CF need to be
referred for audiological test(s) depending on duration of ototoxic medications, however there is
no set guideline that discusses this.
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The comparison of participants using tobramycin for 10 years or less were examined
against baseline levels of normal hearing threshold (≤ 15 dB HL) and is shown in Table 10. This
sample demonstrated significantly worse hearing on a few high-frequency variables in the right
ear (i.e., 14 and 16 kHz) and left ear (i.e., 14 Hz). A comparison of participants using
tobramycin for greater than 10 years compared to baseline normal hearing threshold (≤ 15 dB
HL) is shown in Table 11. This sample demonstrated significant worse hearing on several of the
ultra high-frequency variables in the right ear (i.e., 9 and 11 kHz) and in the left ear (i.e., 8, 9, 10,
11, and 12 kHz). It should be noted that patients with CF who use tobramycin for greater than
10 years have shown to have more frequencies affected, specifically at ultra high-frequencies,
than those who use tobramycin for 10 years or fewer. However, this data is not similar across
ears, with the exception at 14 kHz, for those using tobramycin 10 years or less, and at 9 and 11
kHz for those using tobramycin greater than 10 years. Insufficient affected frequencies were
obtained to prove that the duration of tobramycin intake could potentially be associated to
harming ultra high-frequency regions. However, with more data a clearer picture could be
obtained. McRorie, Bosso, and Randolph’s study (1989) examined patients with CF who were
treated with AGs for more than 20 years compared to those treated less than 20 years and found
elevated thresholds in all frequencies tested in (elevations only in frequencies higher than 16
kHz). This may support the consideration that duration of treatment may have an impact on
potential risks of hearing loss.
AAA and ASHA (AAA, 2009; ASHA, 1994) recommend weekly audiological
evaluations for patients receiving ototoxic medications regardless of duration of use, however,
for the CF population receiving ototoxic medication this recommendation would not be feasible.
As stated previously many of the patients with CF are receiving ototoxic medication may be
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using this medication for years at a time. Having an audiological evaluation every week would
become overly time consuming and increase the already high medical costs for the population.
More data is needed to determine the best course of treatment for this population. When more
information is gathered a testing schedule could be implemented to assure that hearing loss is
monitored without causing difficulty for the patient financially as well as follow up
appointments.
The duration of use of and dosage of tobramycin could be of some importance of whether
or not a patient with CF should have an audiological referral, however, there is no sufficient data
to determine these questions. Various studies have shown a prevalence of SNHL in the CF
population (Mulheran et al, 2001; Cheng et al, 2009; Piltcher et al, 2003) however even with
repeated courses of tobramycin, others have found no significant hearing loss (Mulheran et al,
2001; Scheenstra et al, 2010). Until this could be established more fully it would be
recommended that patients receiving tobramycin whether inhaled or IV should have an annual
audiological evaluation. An audiological evaluation should be performed more often if the
patient notes any change in hearing, tinnitus, fullness in the ear, otalgia or dizziness.
Through this it may be determined at what duration of use in years, is potentially
considered a significant difference that would be significant and may guide the physicians or
audiologists to recommend audiological evaluations more often. Determining when testing may
become more appropriate may be beneficial as the life expectancy of patients with CF increases.
As life expectancy increases the use of tobramycin will increase and the likelihood of ototoxicity
would increase. Therefore an appropriate protocol for patient receiving ototoxic medications
should be established to monitor these possible changes.
Limitations
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There are several limitations to this study that need to be addressed. A lack of
documentation in the medical database system and in patient knowledge regarding certain
demographic related questions was noted. For example, patients with CF estimated the age they
were diagnosed, when they began tobramycin treatment, and/or the amount of antibiotic
medication they received. Many patients with CF had difficulty remembering their treatment
cycle(s) or duration of treatment. In addition to inaccurate subjective in-person responses,
patient chart information in the database was not clear, as the reports would not specify the
dosage of tobramycin. This was especially the case regarding the use of IV tobramycin as
typically this is provided in the hospital and many patients could not accurately determine the
number of times he or she was admitted to the hospital. Hospital records were also inaccessible,
as documentation was maintained by other medical clinics. These variables were considered to
be important and should be concise and accurate across patient history.
Although self-report questionnaires can be a popular methodology in behavioral studies
because of their utility (less time consuming and efficient), there can be many problems with
assessing them. The HHIA item scores (i.e., Total, Emotional, Social/Situational) may have
been affected by the individual’s responses from lack of introspective ability (honesty and
accuracy), interpretation differences of items, limited rating of scale, response bias, and state of
health at time of assessment (e.g., personality, concentration, attitude etc.). These difficulties
should be noted and in need to be countered through a careful design and application of selfreport measures.
More importantly, there was a lack of participants with CF in this study due to the time
constraint of the recruitment period and testing timeframes, lack of motivational factors of
individual’s participation, and availability during restricted participating test sessions. As there
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was already a low statistical power, this negatively affected the likelihood that a nominally
statistically significant finding may truly reflect the effect. Specifically, there was a lack of
patients with CF who demonstrated having objective hearing impairment (i.e., poorer than mild
hearing loss, ranging from moderate to profound). Most of the participants had normal hearing
results, regardless of the various demographic variables or self-report responses analyzed and
discussed. Insufficient participants with various types of hearing impairment were obtained that
would show any potential correlations discussed in this study.
During patient recruitment, it is possible that some patients with CF volunteered due to
his or her perceived hearing loss. While others may have not volunteered due to a lack of
perceived hearing loss. Therefore, some patients with hearing loss may not have been evaluated
and could have provided additional value to the research.
Further Research
Future research should examine the duration of tobramycin usage in the CF population to
further investigate the potential risk correlations to hearing loss. In addition to this, type of
tobramycin intake (i.e., inhalation, IV therapy) should be taken into consideration with a larger
sample size to determine, if any, differences in treatment. It would be interesting to see a
different direction in research in regards to type and/or duration of treatment methods and
ototoxicity monitoring outside of weekly standard guidelines taken from ASHA and AAA. For
example, weekly monitoring compared to monthly or annually ototoxic monitoring and its
possible association to hearing loss. This could notify and aware other medical professionals
about additional factors that could assist in better medical referrals.
Improved recruitment procedures could be implemented to recruit participants with CF
that have various degrees in hearing loss to determine if these participants would be more likely
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to notice differences between tobramycin characteristics, such as intake type and duration in use,
and testing at conventional and at ultra high-frequency pure-tone thresholds. Recruiting a larger
sample size will also benefit results as mentioned and to have a higher statistical power.
A longitudinal study could be useful in the methodology used in this present study to
show any changes in tobramycin intake and audiological evaluation thresholds, specifically at
ultra high-frequency thresholds over time. This could also assist with the referral base of other
medical professionals in regard the duration of use of ototoxicity and when a patient with CF
may be at risk of hearing loss.
CONCLUSION
Adult patients with CF may be at high risk for developing SNHL due to frequent
exposure to AGs. From this present study, self-report questionnaire(s) may not be a valuable
tool to detect potential hearing loss, especially at unnoticed ultra high-frequency regions of
hearing. Therefore further investigation is warranted to determine a protocol that is efficient and
that is cost effective. This should be appropriately available to other medical professionals to
administer to patients with CF in a timely manner (as well as to other health conditions at risk of
hearing loss). As life expectancy in the CF population continues to increase, there may be more
exposure to tobramycin intake; hence patients are at higher risk of developing bilateral SNHL,
potentially impacting his or her quality of life. Since SNHL has been shown to have a significant
impact on social and emotional development, it is recommended that an increased awareness of
the possibility of hearing loss in patients with CF among clinicians, patients and families with
anticipatory planning regarding habilitation of HL should it occur. The CF population should
have routine and longitudinal audiometric evaluations as part of their overall management,
however other factors need to be justified (e.g., duration of ototoxicity by age, onset of treatment,
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type of tobramycin intake etc.) to delineate the optimal treatment without causing potential risk
of hearing loss. The addition of SNHL to the already extensive set of health challenges that
patients with CF face creates a need for intensified identification, prevention, and education,
potentially through changes to the CF care guidelines, which currently varies in recommend
routine audiometric screening. The incidence of hearing loss in the CF population requires
further investigation of etiology and the determination of preventive and treatment measures.
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TABLE 1

*
*
*
*
**
*
*
*.
Correlation is significant at the 0.05 level (2-tailed)
Table 1: Correlation of all participants to baseline hearing threshold of ≤15 dB HL as shown
above. Labeled with an asterisk above, there is significant (p < .05) ultra high-frequency
variables: HF9L, HF10L, HF11R, HF11L, HF12L, HF14R, HF14L, and HF16R.
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TABLE 2

*. Correlation is significant at the 0.05 level and greater than r = .4 (2-tailed)
Table 2: Correlations between HHIA questionnaires subtotal and total scores and results of
conventional audiometry tests (air- and bone-conduction). Columns ending in “E” indicate E
subtotals (emotional), in “S” indicates S subtotals (social/situational), and the HHIA indicates
total score. Values with an asterisk indicate that these correlations are statistically significant (α
< .05). A correlation greater than r = .4 is considered a substantial relationship.
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TABLE 3

*. Correlation is significant at the 0.05 level (2-tailed)
Table 3: Correlations between HHIA questionnaire subtotal and total score and results of ultra
high-frequency audiometry. Columns ending in “E” indicate E subtotals (emotional), in “S”
indicates S subtotals (social/situational), and the HHIA indicates total score. No correlations are
statistically significant (α < .05).
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TABLE 4
4A: Right Ear

4B: Left Ear

Table 4: Comparison of HHIA self-report perception of hearing with pure-tone average hearing
test results from the right ear (Table 4A) and left ear (Table 4B). Normal hearing is ≤15 dB HL.
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TABLE 5

*
*

*. Correlation is significant at the 0.05 level (2-tailed)
Table 5: Comparison of self-reported impairment (i.e., Mild to Moderate Handicap, Severe
Handicap) to baseline normal hearing (≤15 dB HL).
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TABLE 6

*. Correlation is significant at the 0.05 level and greater than r = .4 (2-tailed)
Table 6: Correlation between age of participant diagnosed with CF and age of participant that
received treatment, in comparison to the self-report questionnaire, conventional and ultra highfrequency pure-tone testing.
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TABLE 7

*. Correlation is significant at the 0.05 level (2-tailed)
Table 7: Comparison of inhalation and non-inhalation participants across HHIA scores,
conventional and ultra high-frequency testing. None of the tests are significant; therefore there is
no difference between participants who inhale than those who do not.
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TABLE 8

*. Correlation is significant at the 0.05 level (2-tailed)
Table 8: Comparison of IV and non-IV participants across HHIA scores, conventional and ultra
high-frequency testing. None of the tests are significant, therefore there is no difference between
participants who use IV that those who do not.
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TABLE 9

*. Correlation is significant at the 0.05 level (2-tailed)
Table 9: Comparison of duration of tobramycin intake. Group 1 represents 10 years or less
usage of tobramycin and Group 2 represents more than 10 years usage of tobramycin.
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TABLE 10

*
*
*
*. Correlation is significant at the 0.05 level (2-tailed)
Table 10: Comparison of participants who use tobramycin for 10 years or fewer compared to
baseline threshold ≤ 15 dB HL. There is significant (p < .05) worse hearing in high-frequency
variables: HF14R, HF14L, and HF16R.
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TABLE 11

*
*
*
*
*
*
*

*. Correlation is significant at the 0.05 level (2-tailed)
Table 11: Comparison of participants who use tobramycin for more than 10 years compared to
baseline hearing threshold ≤ 15 dB HL. There is significant (p < .05) worse hearing at ultra
high-frequency variables: APT8L, HF9R, HF9L, HF10L, HF11R, HF11L, and HF12L.
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FIGURE 1

Figure 1: Graphical representation of an audiogram of hearing thresholds (dB HL) across
conventional frequencies (Hz), one displaying the right ear and one for the left ear, as shown
above. Average hearing thresholds from all participants with CF per ear are defined from the red
line and normal hearing thresholds are indicated from the blue line, as shown in key.
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FIGURE 2

Figure 2: Graphical representation of an audiogram of hearing thresholds (dB HL) across ultra
high-frequencies (Hz), one displaying the right ear and one for the left ear, as shown above.
Average hearing thresholds from all participants with CF per ear are defined from the red line
and normal hearing thresholds are indicated from the blue line, as shown in key.
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FIGURE 3

Figure 3: The graphical relationship between the self-report HHIA scores and objective test of
air-conduction pure-tone audiometry for each ear.
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FIGURE 4

Figure: 4: The relationship between the self-report HHIA scores and objective test of boneconduction pure-tone audiometry for each ear.
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FIGURE 5

Figure: 5: The relationship between the self-report HHIA scores and objective test of ultra highfrequency pure-tone audiometry for each ear.

54

Spejcher

FIGURE 6

Figure 6: Graphical representation of an audiogram of average hearing thresholds (dB HL)
across conventional and ultra high-frequencies (Hz), one displaying the right ear and one for the
left ear, as shown above. A key is shown above representing the difference between those
participants with CF taking tobramycin for 10 years or fewer and those taking tobramycin for
more than 10 years, and the blue line indicating normal hearing thresholds.
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APPENDICES
Appendix A: Hearing Handicap Inventory for Adults (HHIA) – Original Version
Granted permission from Dr. Craig Newman, Ph.D.
Revised to use at WUSM Center for Advanced Medicine, Adult Audiology
* = Designated items comprising of the HHIA-S – Screening Version
ITEM
S-1

YES
(4)

Does a hearing problem cause you to use the phone less often than
you would like?

E-2*

Does a hearing problem cause you to feel embarrassed when
meeting new people?

S-3

Does a hearing problem cause you to avoid groups of people?

E-4

Does a hearing problem make you irritable?

E-5*

Does a hearing problem cause you to feel frustrated when talking to
members of your family?

S-6

Does a hearing problem cause you difficulty when attending a
party?

E-7*

Does a hearing problem cause you to feel frustrated when talking to
coworkers, clients, or customer?

E-8*

Do you feel handicapped by a hearing problem?

S-9

Does a hearing problem cause you difficulty when visiting friends,
relatives, or neighbors?

E-10

Does a hearing problem cause you to feel frustrated when talking to
coworkers, client or customers?

S-11*

Does a hearing problem cause you difficulty in the movies or
theater?

E-12

Does a hearing problem cause you to be nervous?

S-13

Does a hearing problem cause you to visit friends, relatives, or
neighbors less often than you would like?

E-14*

Does a hearing problem cause you to have arguments with family
members?
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NO
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S-15*

Does a hearing problem cause you difficulty when listening to TV or
radio?

S-16

Does a hearing problem cause you to go shopping less often than you
would like?

E-17

Does any problem or difficulty with your hearing upset you at all?

E-18

Does a hearing problem cause you to want to be by yourself?

S-19

Does a hearing problem cause you to talk to family members less
often than you would like?

E-20*

Do you feel that any difficulty with your hearing limits or hampers
your personal or social life?

S-21*

Does a hearing problem cause you difficulty when in a restaurant
with relatives or friends?

E-22

Does a hearing problem cause you to feel depressed?

S-23

Does a hearing problem cause you to listen to TV or radio less often
than you would like?

E-24

Does a hearing problem cause you to feel uncomfortable when
talking to friends?

E-25

Does a hearing problem cause you to feel left out when you are with
a group of people?

57

